173 related articles for article (PubMed ID: 20966743)
1. Galactosylated α,β-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity.
Cheng X; Gao F; Xiang J; Jiang X; Chen J; Zhang J
Anticancer Drugs; 2011 Feb; 22(2):136-47. PubMed ID: 20966743
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and toxicological properties of doxorubicin conjugated to [alpha],[beta]-poly[(2-hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice.
Cheng C; Xue W; Diao H; Xia S; Zuo L; He A; Gao F; Huang Z; Chen J; Zhang J
Anticancer Drugs; 2010 Apr; 21(4):362-71. PubMed ID: 20468087
[TBL] [Abstract][Full Text] [Related]
3. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
4. Poly(L-aspartamide)-based reduction-sensitive micelles as nanocarriers to improve doxorubicin content in cell nuclei and to enhance antitumor activity.
Cui C; Xue YN; Wu M; Zhang Y; Yu P; Liu L; Zhuo RX; Huang SW
Macromol Biosci; 2013 Aug; 13(8):1036-47. PubMed ID: 23828842
[TBL] [Abstract][Full Text] [Related]
5. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
7. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.
Garg M; Madan J; Pandey RS; Sardana S; Katyal A; Chandra R
Anticancer Drugs; 2012 Sep; 23(8):836-45. PubMed ID: 22407250
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
9. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
10. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
11. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo.
Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C
J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610
[TBL] [Abstract][Full Text] [Related]
12. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
13. Galactosylated polymeric carriers for liver targeting of sorafenib.
Craparo EF; Sardo C; Serio R; Zizzo MG; Bondì ML; Giammona G; Cavallaro G
Int J Pharm; 2014 May; 466(1-2):172-80. PubMed ID: 24607205
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide releasing d-α-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin.
Song Q; Tan S; Zhuang X; Guo Y; Zhao Y; Wu T; Ye Q; Si L; Zhang Z
Mol Pharm; 2014 Nov; 11(11):4118-29. PubMed ID: 25222114
[TBL] [Abstract][Full Text] [Related]
15. Polyaspartamide-doxorubicin conjugate as potential prodrug for anticancer therapy.
Di Meo C; Cilurzo F; Licciardi M; Scialabba C; Sabia R; Paolino D; Capitani D; Fresta M; Giammona G; Villani C; Matricardi P
Pharm Res; 2015 May; 32(5):1557-69. PubMed ID: 25366547
[TBL] [Abstract][Full Text] [Related]
16. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
18. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
19. Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions.
Ding J; Xiao C; Li Y; Cheng Y; Wang N; He C; Zhuang X; Zhu X; Chen X
J Control Release; 2013 Aug; 169(3):193-203. PubMed ID: 23247039
[TBL] [Abstract][Full Text] [Related]
20. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
